Opdivo injection OK'd for liver cancer patients.
Bristol-Myers Squibb Co. has gained FDA approval for Opdivo (nivolumab) injection for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. HCC is the most common type of liver cancer, and incidence rates are rising, Bristol-Myers Squibb reported. The FDA cleared this Opdivo indication under an accelerated approval process based on tumor response rate and durability of response, the company said. "We are proud to bring the potential for clinically meaningful responses with immuno-oncology therapy to these advanced-stage HCC patients, who have had limited treatment options for years," commented Chris Boerner, U.S. Commercial president at Bristol-Myers Squibb. He added that the approval "marks an important step toward our mission of delivering transformational medicines to treat conditions with a high unmet need."
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Rx Update|
|Publication:||Chain Drug Review|
|Date:||Oct 23, 2017|
|Previous Article:||PhRMA updates drug research for Alzheimer's.|
|Next Article:||Use of High-Cost Rxs Rises.|